THRN — Stock Film
STOCK FILMSCENE 1/11THRN · $10.19
Stock Expert AI presents
THRN
Thorne HealthTech, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Thorne HealthTech, Inc. A quick introduction.

On the stock market since 2021, it operates in the everyday-essentials business. It has 544 employees. Now — the numbers.

on the stock market since 2021
544 employees
$550.6M market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $7 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 7%

This is an established company with proven profits.

THE SALES TREND
Sales are growing, year after year.

Average growth of 31% a year over the last 3 years. Red columns mark years that ended in a loss.

$102.5M
2019
$138.5M
2020
$185.2M
2021
$228.7M
2022
Cash on hand:
$0
Total debt:
$0
The debt outweighs the cash.

The gap is $11.0M. In times of high interest rates, a gap like that can squeeze a company.

Every quarter, analysts set a profit bar.
How many of the last 7 did the company clear?
3 / 7
EXPECTATIONS MET OR BEATEN
3
May 2022
Aug 2022
Nov 2022
Mar 2023
May 2023
Aug 2023
Nov 2023
3 TIMES IN THE LAST 7 QUARTERS
It misses the bar more often than not.
THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit on each sale8/10
WEAK SPOTS
The stock has lost its spark0/10
Little set aside for the future2/10
WORTH WATCHING

R&D Investment: Spending on future research is low.

THE FIVE-YEAR JOURNEY
Bumpy, but the direction is up.

The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.

1
THE BRIGHT SIDE · 1/1
Sales keep climbing

Over the last 3 years, sales grew about 31% a year on average.

1
THE RISKS · 1/3
A rich price tag

The company’s market value is 35 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/3
Executives lean toward selling

Over the last 12 months, executives reported 43 sells against just 5 buys. Not an alarm bell by itself, but a number worth watching.

3
THE RISKS · 3/3
The price sits above analysts’ target

The stock trades 44% above the average analyst price target.

FINALE · THE GRADE
D
0 / 100 · MoonshotScore

On our five-subject report card, THRN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: THRN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film